MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. Financials Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.4 CNY | -2.74% |
|
+3.15% | +2.17% |
| May. 24 | Mabwell Announces 9MW2821 Clinical Data | CI |
| May. 13 | Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,774 | 13,063 | 13,347 | - | - |
| Enterprise Value (EV) 1 | 5,774 | 13,063 | 13,347 | 13,347 | 13,347 |
| P/E ratio | -5.92 x | -12.4 x | -14.5 x | -20.8 x | -101 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 102 x | 39.9 x | 13.5 x | 7.23 x |
| EV / Revenue | - | 102 x | 39.9 x | 13.5 x | 7.23 x |
| EV / EBITDA | - | -13.4 x | -16.6 x | -27.4 x | 388 x |
| EV / FCF | - | -10.2 x | -15.5 x | -21.3 x | 1,495 x |
| FCF Yield | - | -9.82% | -6.45% | -4.7% | 0.07% |
| Price to Book | - | 5.05 x | 8.02 x | 13.1 x | 15 x |
| Nbr of stocks (in thousands) | 399,600 | 399,600 | 399,600 | - | - |
| Reference price 2 | 14.45 | 32.69 | 33.40 | 33.40 | 33.40 |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 127.7 | 334.7 | 991.7 | 1,847 |
| EBITDA 1 | - | -973 | -804.6 | -487.7 | 34.43 |
| EBIT 1 | - | -1,053 | -940.3 | -667.4 | -156.7 |
| Operating Margin | - | -824.53% | -280.92% | -67.3% | -8.48% |
| Earnings before Tax (EBT) 1 | - | -1,056 | -921 | -642.4 | -131.7 |
| Net income 1 | -954 | -1,053 | -919 | -640.8 | -131.4 |
| Net margin | - | -824.94% | -274.55% | -64.62% | -7.11% |
| EPS 2 | -2.440 | -2.640 | -2.298 | -1.604 | -0.3300 |
| Free Cash Flow 1 | - | -1,283 | -860.8 | -627.7 | 8.925 |
| FCF margin | - | -1,004.52% | -257.16% | -63.29% | 0.48% |
| FCF Conversion (EBITDA) | - | - | - | - | 25.92% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -1,283 | -861 | -628 | 8.93 |
| ROE (net income / shareholders' equity) | - | -34.5% | -55.8% | -58.7% | -15% |
| ROA (Net income/ Total Assets) | - | -23.6% | -27.5% | -19.1% | -4.1% |
| Assets 1 | - | 4,464 | 3,348 | 3,364 | 3,205 |
| Book Value Per Share 2 | - | 6.470 | 4.160 | 2.560 | 2.230 |
| Cash Flow per Share 2 | - | -1.960 | -2.980 | -0.9200 | 0.0200 |
| Capex 1 | - | 500 | 120 | 95.1 | 55.1 |
| Capex / Sales | - | 391.51% | 35.88% | 9.59% | 2.98% |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.4
CNY
Average target price
48
CNY
Spread / Average Target
+43.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.17% | 1.84B | |
| +18.72% | 125B | |
| +14.53% | 109B | |
| -2.88% | 24.74B | |
| +4.86% | 22.67B | |
| -9.72% | 18.14B | |
| -41.04% | 16.67B | |
| -11.83% | 16.64B | |
| +1.46% | 13.45B | |
| +24.22% | 11.32B |
- Stock Market
- Equities
- 688062 Stock
- Financials Mabwell (Shanghai) Bioscience Co., Ltd.
